-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: PBMC Hybrid Inoculation Model
Author:
InnoModels Biotechnology
Release time:
2024-01-18
InnoModels Biotechnology has once again broken new ground with the launch of the PBMC Hybrid Inoculation Model, which is leading the way in immunology research. The launch of this model not only signifies the company's leadership in the field of biotechnology, but also provides scientists with a powerful tool to explore all aspects of the immune system in a more comprehensive and in-depth manner.
Technical Highlights of the PBMC Hybrid Inoculation Model
The PBMC hybrid model is a novel model based on Peripheral Blood Mononuclear Cells (PBMCs). It centers on mixing PBMCs from different individuals to simulate complex immune system interactions and provide a more realistic environment for research.
Main features and advantages
1. Diversity and complexity:
The PBMC hybrid inoculation model creates a more diverse and complex immune system environment by mixing PBMCs from different individuals. This helps to more realistically reflect the coping mechanisms of the human immune system in complex disease environments.
2. Simulating interactions:
The model is able to simulate the interactions between various cells within the immune system, including T-cells, B-cells, natural killer cells, and so on. This provides researchers with an in-depth understanding of the synergistic interactions between different cell types.
3. Disease simulation and drug development:
The PBMC hybrid inoculation model can be used to simulate a variety of disease environments, including immune-related diseases, infectious diseases, and so on. Meanwhile, the model can also be applied to drug development to help scientists evaluate the effects of drug candidates more comprehensively and efficiently.

Scientific Applications and Future Prospects
1. Disease mechanism analysis:
The PBMC hybrid inoculation model provides a powerful tool for in-depth analysis of disease mechanisms. By simulating real immune system interactions, researchers can better understand the mechanisms of disease occurrence and development.
2. Drug individualization testing:
The diversity of the model makes it an ideal platform for drug individualization testing. Researchers can use PBMCs from different individuals to test the differences in the effects of drugs among different individuals, providing a basis for personalized treatment.
3. Future direction of innovation:
InnoModels Biotechnology is committed to continuously advancing the research of the PBMC hybrid inoculation model to further enhance its application value in the field of immune research. In the future, we are confident that we can promote the development of immunology through this innovative tool.
Conclusion
The launch of the PBMC hybrid inoculation model not only demonstrates the innovative strength of InnoModels Biotechnology, but also brings new opportunities to the global immunology research field. The diversity and complexity of this model provides scientists with a more realistic and reliable research platform, which is expected to drive new breakthroughs in the field of immunology.
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd